Abstract

Background: Procalcitonin (PCT), an amino acid protein precursor of calcitonin hormone released by thyroid C cells or other body cells, can be used as a marker for diagnosing infection. PCT has a suggestive role in diagnosing diabetic foot infection alone or in combination with other markers of infection. Aim: We aimed to evaluate the roles of interleukin-6 (IL-6), CRP, and PCT levels in the differential diagnosis of the patients with infected diabetic foot ulcer (IDFU) and non-infected diabetic foot ulcer (NIDFU) and to compare those with C-reactive protein (CRP), white blood cell (WBC), and erythrocyte sedimentation rate (ESR). Methods: A total of 95 subjects with DFU and NIDFU were enrolled. WBC count, ESR, CRP, and PCT were done for all subjects at admission after obtaining informed consent. Patients over 18 years with a diagnosis of type 2 diabetes mellitus and DFU who were followed up in our hospital were included in the study. In addition to this patient group, patients with diabetes but without DFU were determined as the control group. Results: Twenty nine patients with IDFU, 29 patients with NIDFU, and 43 patients as the control group were included in the study. Fifty-six point three percent of the patients who participated in the study were males, and the mean age was 62.87 ± 10.99 years. WBC, ESR, CRP, and IL-6 levels of the cases with IDFU were determined to be significantly higher compared to the cases in NIDFU (p <0.001). The area under the ROC curve (AUROC) value was highest for CRP (p <0.001), and the best cut-off value for CRP was 36 m/L. The best cut-off values for IL-6, ESR, and WBC were 109.4 pg/mL, 53 mm/h, and 13.7 (103 μ/L), respectively. Conclusion: Serum PCT levels were not found to be effective in the discrimination of IDFU and NIDFU. Serum IL-6 level seems to be one promising inflammatory markers in the discrimination of IDFU. Based on our results, we conclude that PCT has a valuable role in diagnosing infection in DFUs.

References

1. B. A. Lipsky, A. R. Berendt, P. B. Cornia et al., “2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections,” Clinical Infectious Diseases, vol. 54, pp. 132–173, 2012.
2. D. G. Armstrong, J. Wrobel, and J. M. Robbins, “Guest editorial: are diabetes-related wounds and amputations worse than cancer?,” International Wound Journal, vol. 4, no. 4, pp. 286- 287, 2007.
3. N. C. Schaper, J. J. Van Netten, J. Apelqvist, B. A. Lipsky, K. Bakker, and International Working Group on the Diabetic Foot, “Prevention and management of foot problems in diabetes: a Summary Guidance for Daily Practice 2015, based on the IWGDF Guidance Documents,” Diabetes Metabolism Research and Reviews, vol. 32, Supplement S1, pp. 7–15, 2016.
4. L. A. Lavery, D. G. Armstrong, D. P. Murdoch, E. J. Peters, and B. A. Lipsky, “Validation of the Infectious Diseases Society of America’s diabetic foot infection classification system,” Clinical Infectious Diseases, vol. 44, no. 4, pp. 562–565, 2007.
5. D. K. Wukich, K. B. Hobizal, and M. M. Brooks, “Severity of diabetic foot infection and rate of limb salvage,” Foot & Ankle International, vol. 34, no. 3, pp. 351–358, 2013.
6. A. H. Widatalla, S. E. Mahadi, M. A. Shawer, H. A. Elsayem, and M. E. Ahmed, “Implementation of diabetic foot ulcer classification system for research purposes to predict lower extremity amputation,” International Journal of Diabetes in Developing Countries, vol. 29, no. 1, pp. 1–5, 2009.
7. N. C. Schaper, “Diabetic foot ulcer classification system for research purposes: a progress report on criteria for including patients in research studies,” Diabetes/Metabolism Research and Reviews, vol. 20, pp. S90–S95, 2004.
8. J. Aragón-Sánchez, “Seminar review: a review of the basis of surgical treatment of diabetic foot infections,” The International Journal of Lower Extremity Wounds, vol. 10, no. 1, pp. 33–65, 2011.
9. N. Jonaidi Jafari, M. Safaee Firouzabadi, M. Izadi, M. S. Safaee Firouzabadi, and A. Saburi, “Can procalcitonin be an accurate diagnostic marker for the classification of diabetic foot ulcers?,” International Journal of Endocrinology and Metabolism, vol. 12, article e13376, 2014.
10. L. Simon, F. Gauvin, D. K. Amre, P. Saint-Louis, and J. Lacroix, “Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis,” Clinical Infectious Diseases, vol. 39, no. 2, pp. 206–217, 2004.
11. A. Jeandrot, J. L. Richard, C. Combescure et al., “Serum procalcitonin and C-reactive protein concentrations to distinguish mildly infected from non-infected diabetic foot ulcers: a pilot study,” Diabetologia, vol. 51, no. 2, pp. 347–352, 2008.
12. G. Uzun, E. Solmazgul, H. Curuksulu et al., “Procalcitonin as a diagnostic aid in diabetic foot infections,” The Tohoku Journal of Experimental Medicine, vol. 213, no. 4, pp. 305–312, 2007.
13. M. Massara, G. De Caridi, R. Serra et al.,“The role of procalcitonin as a marker of diabetic foot ulcer infection,” International Wound Journal, vol. 14, no. 1, pp. 31–34, 2017.
14. F. A. Altay, İ. Sencan, “Does treatment affect the levels of serum interleukin-6, interleukin-8 and procalcitonin in diabetic foot infection? A pilot study,” Journal of Diabetes and its Complications, vol. 26, no. 3, pp. 214–218, 2012.
15. C. Buck, J. Bundschu, H. Gallati, P. Bartmann, and F. Pohlandt, “Interleukin-6: a sensitive parameter for the early diagnosis of neonatal bacterial infection,” Pediatrics, vol. 93, no. 1, pp. 54–58, 1994.
16. R. C. Silveira and R. S. Procianoy, “Evaluation of interleukin-6, tumour necrosis factor-α and interleukin-1β for early diagnosis of neonatal sepsis,” Acta Paediatrica, vol. 88, no. 6, pp. 647– 650, 1999.
17. C. Weigelt, B. Rose, U. Poschen et al.,“Immune mediators in patients with acute diabetic foot syndrome,” Diabetes Care, vol. 32, no. 8, pp. 1491–1496, 2009.
18. M. W. Mosesson, K. R. Siebenlist, and D. A. Meh,“The structure and biological features of fibrinogen and fibrin,” Annals of the New York Academy of Sciences, vol. 936, pp. 11–30, 2001.
19. X. H. Li, L. Y. Guan, H. Y. Lin et al.,“Fibrinogen: a marker in predicting diabetic foot ulcer severity,” Journal of Diabetes Research, vol. 2016, Article ID 2358321, 5 pages, 2016.
20. M. L. Grayson, G. W. Gibbons, K. Balogh, E. Levin, and A. W. Karchmer,“Probing to bone in infected pedal ulcers. A clinical sign of underlying osteomyelitis in diabetic patients,” Journal of the American Medical Association, vol. 273, no. 9, pp. 721– 723, 1995.
21. K. Saeed, N. Ahmad, and M. Dryden,“The value of procalcitonin measurement in localized skin and skin structure infection, diabetic foot infections, septic arthritis and osteomyelitis,” Expert Review of Molecular Diagnostics, vol. 14, no. 1, pp. 47–54, 2014.
22. A. W. Glaudemans, I. Uçkay, and B. A. Lipsky,“Challenges in diagnosing infection in the diabetic foot,” Diabetic Medicine, vol. 32, no. 6, pp. 748–759, 2015.
23. R. Rattan and D. Nayak, “High levels of plasma malondialdehyde, protein carbonyl, and fibrinogen have prognostic potential to predict poor outcomes in patients with diabetic foot wounds: a preliminary communication,” The International Journal of Lower Extremity Wounds, vol. 7, no. 4, pp. 198–203, 2008.
24. J. H. Park, D. H. Suh, H. J. Kim, and G. W. Choi,“Role of procalcitonin in infected diabetic foot ulcer,” Diabetes Research and Clinical Practice, vol. 128, pp. 51–57, 2017.
25. Abbas M, Uckay I, Lipsky BA. In diabetic foot infections antibiotics are to treat infection, not to heal wounds. Expert Opin Pharmacother 2015; 16:821–832.
26. Singh S, Pai DR, Yuhhui C. Diabetic foot ulcer − diagnosis and management. Clin Res Foot Ankle 2013; 1:120.
27. Saleem SM, Khan SS, Jan SS. Role of serum procalcitonin level in early diagnosis of bacterial pneumonia in children, a hospital-based study. Int J Res Med Sci 2016; 4:1518–1521.